Updates in the Treatment of HR+ Breast Cancer : Episode 5
Opinion
Video
Potential With Individual Tumor Sequencing With Bespoke Testing Methodologies and ctDNA
Author(s):
A panel of experts discuss the potential of individual tumor sequencing with bespoke testing methodologies.
EP: 1.Expert Insights on Biomarker Testing in Early-Stage Breast Cancer
EP: 2.Insights from TAILORx and RxPONDER in Guiding Treatment in Early-Stage HR+ Breast Cancer
EP: 3.Advancements in Adjuvant Therapy in Early-Stage HR+ Breast Cancer
EP: 4.Expert Perspectives on Optimizing Biomarker Testing in Advanced HR+/HER2- Breast Cancer
Now Viewing
EP: 5.Potential With Individual Tumor Sequencing With Bespoke Testing Methodologies and ctDNA
EP: 6.Updates in Treatment Approaches With CDK4/6 Inhibitors in HR+ Breast Cancer
EP: 7.Expert Perspectives in Navigating Treatment Strategies with CDK4/6 Inhibitors in HR+ Breast Cancer
EP: 8.Navigating 2L Treatment Strategies with Oral SERDs and Elasestrant
EP: 9.Treatment Advancements Targeting the PI3K/AKT Pathway in HR+ Breast Cancer
EP: 10.ADC-Based Treatment Strategies HR+Breast Cancer:Updates from DESTINY-Breast06
EP: 11.Expert Perspectives in Sequencing ADC-Based Therapies in HR+ Breast Cancer
EP: 12.Looking Ahead: Expert Future Perspectives in the HR+ Breast Cancer Landscape
Video content above is prompted by the following:
- What are the available first- or second-line treatment options for HR+ advanced/metastatic breast cancer? (CDK4/6i +/- ET, etc.)
Related Videos
Related Content
%20(2)%201-Recovered-Recovered.jpg?fit=crop&auto=format)
